Latigo Biotherapeutics adopts amended and restated bylaws tied to IPO close

• Latigo Biotherapeutics adopted amended and restated bylaws effective Aug. 10, 2026 in connection with its IPO closing.
• It also filed an amended and restated certificate of incorporation in Delaware, effective immediately before the IPO close.
• The IPO sold 19,200,000 common shares at USD 18 per share, raising about USD 345.6 million in gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342321), on August 10, 2026, and is solely responsible for the information contained therein.